Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Elahe Taki, Faezeh Soleimani, Arezoo Asadi, Hossein Ghahramanpour, Ali Namvar & Mohsen Heidary. (2022) Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. Expert Review of Anti-infective Therapy 20:8, pages 1135-1147.
Read now
Read now
Diana Canetti & Vincenzo Spagnuolo. (2021) An evaluation of cabotegravir for HIV treatment and prevention. Expert Opinion on Pharmacotherapy 22:4, pages 403-414.
Read now
Read now
Cristina Fernandez & Clare L van Halsema. (2019) Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV/AIDS - Research and Palliative Care 11, pages 179-192.
Read now
Read now
Nuggehally R. Srinivas. (2016) Interspecies scaling of excretory amounts using allometry – retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica 46:9, pages 784-792.
Read now
Read now
Melinda J. Reese, Gary D. Bowers, Joan E. Humphreys, Elizabeth P. Gould, Susan L. Ford, Lindsey O. Webster & Joseph W. Polli. (2016) Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica 46:5, pages 445-456.
Read now
Read now
Articles from other publishers (35)
Christina G. Rivera, John D. Zeuli, Bradley L. Smith, Tanner M. Johnson, Ramona Bhatia, Ashley O. Otto & Zelalem Temesgen. (2023) HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic. Drugs.
Crossref
Crossref
Ghulam Shabir, Aamer Saeed, Wajeeha Zahid, Fatima Naseer, Zainab Riaz, Nafeesa Khalil, Muneeba & Fernando Albericio. (2023) Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022). Pharmaceuticals 16:8, pages 1162.
Crossref
Crossref
John O. Miners, Thomas M. Polasek, Julie-Ann Hulin, Andrew Rowland & Robyn Meech. (2023) Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance. Pharmacology & Therapeutics 248, pages 108459.
Crossref
Crossref
Marco T.A. Abbate, Inken K. Ramöller, Akmal H. Sabri, Alejandro J. Paredes, Aaron J. Hutton, Peter E. McKenna, Ke Peng, Jessica A. Hollett, Helen O. McCarthy & Ryan F. Donnelly. (2023) Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND). International Journal of Pharmaceutics 640, pages 123005.
Crossref
Crossref
Alexa Vyain Zhao, Rustin D. Crutchley, Rakesh Chowdary Guduru, Kathy Ton, Tammie Lam & Amy Cheng Min. (2022) A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology 19:1.
Crossref
Crossref
Yifan Yu, Kristin L. Bigos, Mark A. Marzinke, Raphael J. Landovitz, Marybeth McCauley, Susan Ford, Craig W. Hendrix, Robert R. Bies & Ethel D. Weld. (2022) A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP. British Journal of Clinical Pharmacology 88:10, pages 4623-4632.
Crossref
Crossref
Mary B. McGuckin, Jiawen Wang, Rand Ghanma, Nuoya Qin, Santiago D. Palma, Ryan F. Donnelly & Alejandro J. Paredes. (2022) Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. Journal of Controlled Release 345, pages 334-353.
Crossref
Crossref
Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang, Melanie Paff, William R. Spreen & Susan L. Ford. (2022) Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men. Antimicrobial Agents and Chemotherapy 66:3.
Crossref
Crossref
Erkka Järvinen, Feng Deng, Wilma Kiander, Alli Sinokki, Heidi Kidron & Noora Sjöstedt. (2022) The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates. Frontiers in Pharmacology 12.
Crossref
Crossref
Nagsen Gautam, JoEllyn M. McMillan, Devendra Kumar, Aditya N. Bade, Qiaoyu Pan, Tanmay A. Kulkarni, Wenkuan Li, Brady Sillman, Nathan A. Smith, Bhagya L. Dyavar Shetty, Adam Szlachetka, Benson J. Edagwa, Howard E. Gendelman & Yazen Alnouti. (2021) Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications 12:1.
Crossref
Crossref
Micaela B. Reddy, Michael B. Bolger, Grace Fraczkiewicz, Laurence Del Frari, Laibin Luo, Viera Lukacova, Amitava Mitra, Joyce S. Macwan, Jim M. Mullin, Neil Parrott & Aki T. Heikkinen. (2021) PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates. Pharmaceutics 13:9, pages 1325.
Crossref
Crossref
Terri L. Levien, Audrian Santos & Danial E. Baker. (2021) Formulary Drug Review: Cabotegravir. Hospital Pharmacy, pages 001857872110295.
Crossref
Crossref
Daryl Hodge, David J. Back, Sara Gibbons, Saye H. Khoo & Catia Marzolini. (2021) Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clinical Pharmacokinetics 60:7, pages 835-853.
Crossref
Crossref
Herana Kamal Seneviratne, Allyson N. Hamlin, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y. Liu, Irene Kuo, Mina C. Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Adeola Adeyeye, Alex R. Rinehart, Marybeth McCauley, Joseph S. Eron, Myron S. Cohen, Raphael J. Landovitz, Craig W. Hendrix & Namandjé N. Bumpus. (2021) Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. ACS Pharmacology & Translational Science 4:1, pages 226-239.
Crossref
Crossref
Kimberly K. Scarsi, Joshua P. Havens, Anthony T. Podany, Sean N. Avedissian & Courtney V. Fletcher. (2020) HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. Drugs 80:16, pages 1649-1676.
Crossref
Crossref
Cheríe S. BlairSue LiGordon ChauLeslie CottlePaul RichardsonMark A. MarzinkeSusan H. EshlemanAdeola AdeyeyeAlex R. Rinehart, David Margolis, Marybeth McCauleyCraig W. HendrixRaphael J. Landovitz. (2020) Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. JAIDS Journal of Acquired Immune Deficiency Syndromes 85:1, pages 93-97.
Crossref
Crossref
W.M.A. Niessen. (2020) Tandem mass spectrometry of small-molecule antiviral drugs: 1. HIV-related antivirals. International Journal of Mass Spectrometry 455, pages 116370.
Crossref
Crossref
Anthony T. Podany, Kimberly K. Scarsi, Michelle M. Pham & Courtney V. Fletcher. (2020) Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review. Clinical Pharmacokinetics 59:9, pages 1085-1107.
Crossref
Crossref
Parul Patel, Zhengyu Xue, Karen S King, Laura Parham, Susan Ford, Yu Lou, Kalpana K Bakshi, Kenneth Sutton, David Margolis, Arlene R Hughes & William R Spreen. (2020) Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir. Journal of Antimicrobial Chemotherapy.
Crossref
Crossref
Meredith E. Clement, Ryan Kofron & Raphael J. Landovitz. (2020) Long-acting injectable cabotegravir for the prevention of HIV infection. Current Opinion in HIV and AIDS 15:1, pages 19-26.
Crossref
Crossref
Brandon Dionne. (2019) Key Principles of Antiretroviral Pharmacology. Infectious Disease Clinics of North America 33:3, pages 787-805.
Crossref
Crossref
Mitesh Patel, H. Christian Eberl, Andrea Wolf, Esaie Pierre, Joseph W. Polli & Maciej J. Zamek-Gliszczynski. (2019) Mechanistic Basis of Cabotegravir–Glucuronide Disposition in Humans. Journal of Pharmacology and Experimental Therapeutics 370:2, pages 269-277.
Crossref
Crossref
Fernanda P. Pons-Faudoa, Antons Sizovs, Nicola Di Trani, Jesus Paez-Mayorga, Giacomo Bruno, Jessica Rhudy, Madhuri Manohar, Kevin Gwenden, Cecilia Martini, Corrine Ying Xuan Chua, Greta Varchi, Mark A. Marzinke & Alessandro Grattoni. (2019) 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. Journal of Controlled Release 306, pages 89-96.
Crossref
Crossref
Ridhi Parasrampuria, Susan L. Ford, Yu Lou, Caifeng Fu, Kalpana K. Bakshi, Allan R. Tenorio, Christine Trezza, William R. Spreen & Parul Patel. (2019) A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants. Clinical Pharmacology in Drug Development 8:5, pages 674-681.
Crossref
Crossref
Jafar Sadik B. Shaik, Susan L. Ford, Yu Lou, Zhiping Zhang, Kalpana K. Bakshi, Allan R. Tenorio, Christine Trezza, William R. Spreen & Parul Patel. (2019) A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls. Clinical Pharmacology in Drug Development 8:5, pages 664-673.
Crossref
Crossref
Dario Cattaneo & Cristina Gervasoni. (2018) Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics 44:3, pages 319-327.
Crossref
Crossref
Aaron S. Devanathan, Daijha J.C. Anderson, Mackenzie L. Cottrell, Erin M. Burgunder, Ashley C. Saunders & Angela D.M. Kashuba. (2019)
Contemporary Drug–Drug Interactions in
HIV
Treatment
. Clinical Pharmacology & Therapeutics 105:6, pages 1362-1377.
Crossref
Crossref
Stephanie N. Liu, Jessica Bo Li Lu, Christy J. W. Watson, Philip Lazarus, Zeruesenay Desta & Brandon T. Gufford. (2019) Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors. Drug Metabolism and Disposition 47:5, pages 535-544.
Crossref
Crossref
Parul Patel, Susan L. Ford, Yu Lou, Kalpana Bakshi, Allan R. Tenorio, Zhiping Zhang, Rennan Pan & William Spreen. (2018) Effect of a High‐Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir. Clinical Pharmacology in Drug Development 8:4, pages 443-448.
Crossref
Crossref
Ruben van der Galiën, Rob ter Heine, Rick Greupink, Stein J. Schalkwijk, Antonius E. van Herwaarden, Angela Colbers & David M. Burger. (2018) Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. Clinical Pharmacokinetics 58:3, pages 309-323.
Crossref
Crossref
Rajith K. R. Rajoli, David J. Back, Steve Rannard, Caren Freel Meyers, Charles Flexner, Andrew Owen & Marco Siccardi. (2017) In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. Clinical Pharmacokinetics 57:2, pages 255-266.
Crossref
Crossref
Tian Zhou, Hang Su, Prasanta Dash, Zhiyi Lin, Bhagya Laxmi Dyavar Shetty, Ted Kocher, Adam Szlachetka, Benjamin Lamberty, Howard S. Fox, Larisa Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, R. Lee Mosley, Yazen Alnouti, Benson Edagwa & Howard E. Gendelman. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151, pages 53-65.
Crossref
Crossref
Christine Trezza, Susan L. Ford, Elizabeth Gould, Yu Lou, Chuyun Huang, James M. Ritter, Ann M. Buchanan, William Spreen & Parul Patel. (2017) Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. British Journal of Clinical Pharmacology 83:7, pages 1499-1505.
Crossref
Crossref
Javier Saurina & Sonia Sentellas. (2017) Strategies for metabolite profiling based on liquid chromatography. Journal of Chromatography B 1044-1045, pages 103-111.
Crossref
Crossref
Yu Lou, Ann M. Buchanan, Shuguang Chen, Susan L. Ford, Elizabeth Gould, David Margolis, William R. Spreen & Parul Patel. (2016) Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects. Clinical Pharmacology in Drug Development 5:6, pages 509-516.
Crossref
Crossref